Drug Trial Radar · NCT01576666
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jul 2012
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic breast cancer, advanced pancreatic adenocarcinoma, metastatic colorectal cancer and recurrent glioblastoma multiforme).
Conditions
- Dose Escalation
- Safety
- Preliminary Efficacy
- Advanced Solid Tumors
- Metastatic Breast Cancer
- Advanced Pancreatic Adenocarcinoma
- Metastatic Colorectal Cancer
- Recurrent Glioblastoma Multiforme
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Triple Negative Metastatic Breast Cancer
- Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225Drug
BKM120Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting ToxicitiesTime frame: 6 weeks (42 days)
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center SC
Los Angeles, California
University of California San Francisco UCSF (SC)
San Francisco, California
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4
Tampa, Florida
Dana Farber Cancer Institute Dana SC
Boston, Massachusetts
Mayo Clinic - Rochester Division of Hematology
Rochester, Minnesota
Duke University Medical Center Duke - Baker
Durham, North Carolina
Willamette Valley Clinical Studies Williamette Valley Cancer
Eugene, Oregon
Northwest Cancer Specialists Northwest Cancer
Portland, Oregon
Fox Chase Cancer Center FCCC
Philadelphia, Pennsylvania
Texas Oncology Midtown Texas Oncology
Dallas, Texas
Sammons Cancer Center - Texas Oncology SC-2
Dallas, Texas
University of Texas/MD Anderson Cancer Center SC-3
Houston, Texas
University of Utah / Huntsman Cancer Institute Huntsman
Salt Lake City, Utah
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Glasgow, United Kingdom
Novartis Investigative Site
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.